16
total announcements
ALPA.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 15 Oct 2026
Market Cap
₹121 Cr
P/E (TTM)
34.2
P/E (Forward)
10.8
EPS (TTM)
₹1.68
52W Low
₹46.10
52W High
₹93.85
Dividend Yield
0.00%
Beta
0.91
Price / Book
0.6
Debt / Equity
1.3
Revenue (TTM)
₹111 Cr
Gross Margin
25.54%
Operating Margin
-19.54%
Alpa Laboratories Limited
Alpa Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming dematerialization of securities and listing on the stock exchange.
Alpa Laboratories Limited
Alpa Laboratories Limited has submitted the Exchange a copy Scrutinizer's report of the 38th Annual General Meeting held on September 30, 2026. The company has informed the Exchange regarding voting results.
Alpa Laboratories Limited
Alpa Laboratories Limited held its 38th Annual General Meeting on September 30, 2026, where the company's audited standalone and consolidated financial statements for the year ended March 31, 2026, were adopted. The meeting also approved the appointment of a new director, Mrs. Radhika Biyani, and the ratification of the remuneration of the cost auditors. Additionally, the company received approval to grant loans, guarantees, securities, and investments up to Rs. 160 crores.
Alpa Laboratories Limited
Alpa Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Alpa Laboratories Limited
Alpa Laboratories Limited has informed the Exchange regarding the appointment of Ms. Diksha Jaswani as Company Secretary cum Compliance Officer of the company, effective September 17, 2026.
Alpa Laboratories Limited
Alpa Laboratories Limited has announced the record date for its 38th Annual General Meeting (AGM) to be held on September 30, 2026, with the register of members and share transfer book closed from September 23 to 30, 2026.
Alpa Laboratories Limited
Alpa Laboratories Limited has informed the Exchange regarding the appointment of Mrs. Radhika Biyani as a Non-Executive Director of the company, effective September 05, 2026. The appointment is subject to the approval of the members of the Company at the ensuing General Meeting or by way of postal ballot.
Alpa Laboratories Limited
Alpa Laboratories Limited has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with a net profit of Rs. 103.84 crores and a basic and diluted EPS of Rs. 0.52.
Alpa Laboratories Limited
Alpa Laboratories Limited has informed the Exchange regarding a clarification on the board meeting date, correcting a typographical error that mentioned the meeting as scheduled for August 14, 2026, instead of August 13, 2026.
Alpa Laboratories Limited
Alpa Laboratories Limited has informed the Exchange about General Updates, including approval in principle for exploring the proposed promotion and incorporation of an overseas company in Nigeria, Alpa Biopharm Limited, in association with Blueseal Pharmaceuticals Limited, Nigeria.
Alpa Laboratories Limited
Alpa Laboratories Limited has responded to a clarification request from the Exchange regarding its financial results for the quarter ended 31-Mar-2026, as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Alpa Laboratories Limited
Alpa Laboratories Limited has informed the Exchange regarding the cessation of Ms. Jyoti Jain as a Non-Executive Independent Director of the company, effective July 21, 2026, due to the completion of her tenure.
Alpa Laboratories Limited
Alpa Laboratories Limited has informed the Exchange regarding Cessation of Ms Yashoda Patidar as Company Secretary & Compliance Officer of the company w.e.f. July 26, 2026.
Alpa Laboratories Limited
Alpa Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window for dealing in securities/shares of the company shall remain closed from 1st July, 2026 till 48 hours after the declaration of the Financial Results by the Company for the First Quarter ending June 30, 2026.
Alpa Laboratories Limited
NSE-listed Alpa Laboratories Limited has been sought clarification by the exchange for the quarter ended 31-Mar-2026 regarding Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company is required to clarify certain information, but its response is awaited.
Alpa Laboratories Limited
Alpa Laboratories Limited has submitted a disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 to the exchange. This regulation mandates promoters to disclose details of any shares they have encumbered in the company. The submission signifies compliance with regulatory obligations. While this announcement doesn't detail the specifics, such filings are important for investors as they provide transparency on potential changes in promoter shareholdings or pledges, which can influence market perception.